Previous close | 0.0400 |
Open | 0.0400 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 5.00 |
Expiry date | 2025-01-17 |
Day's range | 0.0400 - 0.0400 |
Contract range | N/A |
Volume | |
Open interest | 9.69k |
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new supported and/or funded research on the clinical impact of VASCEPA®/VAZKEPA (icosapent ethyl) in patients with diabetes and high cardiovascular risk and the anti-Lp(a) oxidation mechanistic effects of eicosapentaenoic acid (EPA) will be presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting September 9 – 13, 2024 in Madrid, Sp
DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced new supported and/or funded subgroup data from the landmark REDUCE-IT® cardiovascular outcomes trial with VASCEPA®/VAZKEPA® (icosapent ethyl), as well as abstracts showcasing the mechanistic activity of eicosapentaenoic acid (EPA) that will be presented at the European Society of Cardiology (ESC) Congress in London, United Kingdom, August 30 – September 2, 2024. The accep